218 related articles for article (PubMed ID: 17851565)
1. The effect of herbal medicine baicalin on pharmacokinetics of rosuvastatin, substrate of organic anion-transporting polypeptide 1B1.
Fan L; Zhang W; Guo D; Tan ZR; Xu P; Li Q; Liu YZ; Zhang L; He TY; Hu DL; Wang D; Zhou HH
Clin Pharmacol Ther; 2008 Mar; 83(3):471-6. PubMed ID: 17851565
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a potential transporter-mediated drug interaction between rosuvastatin and pradigastat, a novel DGAT-1 inhibitor.
Kulmatycki K; Hanna I; Meyers D; Salunke A; Movva A; Majumdar T; Natrillo A; Vapurcuyan A; Rebello S; Sunkara G; Chen J
Int J Clin Pharmacol Ther; 2015 May; 53(5):345-55. PubMed ID: 25740267
[TBL] [Abstract][Full Text] [Related]
3. Hepatic nuclear factor 1alpha inhibitor ursodeoxycholic acid influences pharmacokinetics of the organic anion transporting polypeptide 1B1 substrate rosuvastatin and bilirubin.
He YJ; Zhang W; Tu JH; Kirchheiner J; Chen Y; Guo D; Li Q; Li ZY; Chen H; Hu DL; Wang D; Zhou HH
Drug Metab Dispos; 2008 Aug; 36(8):1453-6. PubMed ID: 18443034
[TBL] [Abstract][Full Text] [Related]
4. Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans.
Choi JH; Lee MG; Cho JY; Lee JE; Kim KH; Park K
Clin Pharmacol Ther; 2008 Feb; 83(2):251-7. PubMed ID: 17568401
[TBL] [Abstract][Full Text] [Related]
5. Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in humans.
Takeuchi K; Sugiura T; Matsubara K; Sato R; Shimizu T; Masuo Y; Horikawa M; Nakamichi N; Ishiwata N; Kato Y
Drug Metab Dispos; 2014 Apr; 42(4):726-34. PubMed ID: 24440960
[TBL] [Abstract][Full Text] [Related]
6. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin.
Prueksaritanont T; Chu X; Evers R; Klopfer SO; Caro L; Kothare PA; Dempsey C; Rasmussen S; Houle R; Chan G; Cai X; Valesky R; Fraser IP; Stoch SA
Br J Clin Pharmacol; 2014 Sep; 78(3):587-98. PubMed ID: 24617605
[TBL] [Abstract][Full Text] [Related]
7. Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril.
Maeda K; Ieiri I; Yasuda K; Fujino A; Fujiwara H; Otsubo K; Hirano M; Watanabe T; Kitamura Y; Kusuhara H; Sugiyama Y
Clin Pharmacol Ther; 2006 May; 79(5):427-39. PubMed ID: 16678545
[TBL] [Abstract][Full Text] [Related]
8. Eltrombopag increases plasma rosuvastatin exposure in healthy volunteers.
Allred AJ; Bowen CJ; Park JW; Peng B; Williams DD; Wire MB; Lee E
Br J Clin Pharmacol; 2011 Aug; 72(2):321-9. PubMed ID: 21434975
[TBL] [Abstract][Full Text] [Related]
9. Differential effect of genetic variants of Na(+)-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors.
Choi MK; Shin HJ; Choi YL; Deng JW; Shin JG; Song IS
Xenobiotica; 2011 Jan; 41(1):24-34. PubMed ID: 20946088
[TBL] [Abstract][Full Text] [Related]
10. Drug-drug interactions between rosuvastatin and oral antidiabetic drugs occurring at the level of OATP1B1.
van de Steeg E; Greupink R; Schreurs M; Nooijen IH; Verhoeckx KC; Hanemaaijer R; Ripken D; Monshouwer M; Vlaming ML; DeGroot J; Verwei M; Russel FG; Huisman MT; Wortelboer HM
Drug Metab Dispos; 2013 Mar; 41(3):592-601. PubMed ID: 23248200
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of organic anion transporting polypeptide 1B1 and 1B3 humanized mice as a translational model to study the pharmacokinetics of statins.
Salphati L; Chu X; Chen L; Prasad B; Dallas S; Evers R; Mamaril-Fishman D; Geier EG; Kehler J; Kunta J; Mezler M; Laplanche L; Pang J; Rode A; Soars MG; Unadkat JD; van Waterschoot RA; Yabut J; Schinkel AH; Scheer N
Drug Metab Dispos; 2014 Aug; 42(8):1301-13. PubMed ID: 24855184
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study.
Zhang W; Deng S; Chen XP; Zhou G; Xie HT; He FY; Cao D; Li YJ; Zhou HH
Clin Ther; 2008 Jul; 30(7):1283-9. PubMed ID: 18691987
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of cobicistat boosted-elvitegravir administered in combination with rosuvastatin.
Custodio JM; Wang H; Hao J; Lepist EI; Ray AS; Andrews J; Ling KH; Cheng A; Kearney BP; Ramanathan S
J Clin Pharmacol; 2014 Jun; 54(6):649-56. PubMed ID: 24375014
[TBL] [Abstract][Full Text] [Related]
14. Effect of silymarin supplement on the pharmacokinetics of rosuvastatin.
Deng JW; Shon JH; Shin HJ; Park SJ; Yeo CW; Zhou HH; Song IS; Shin JG
Pharm Res; 2008 Aug; 25(8):1807-14. PubMed ID: 18236139
[TBL] [Abstract][Full Text] [Related]
15. Effect of organic anion-transporting polypeptide 1B1 (OATP1B1) polymorphism on the single- and multiple-dose pharmacokinetics of enalapril in healthy Chinese adult men.
Tian L; Liu H; Xie S; Jiang J; Han L; Huang Y; Li Y
Clin Ther; 2011 May; 33(5):655-63. PubMed ID: 21665049
[TBL] [Abstract][Full Text] [Related]
16. [Effect of OATP1B1 521T --> C heterogenesis on pharmacokinetic characterstics of rosuvastatin in Chinese volunteers].
Sui SM; Wen JH; Li XH; Xiong YQ
Yao Xue Xue Bao; 2011 Jun; 46(6):695-700. PubMed ID: 21882531
[TBL] [Abstract][Full Text] [Related]
17. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
Schneck DW; Birmingham BK; Zalikowski JA; Mitchell PD; Wang Y; Martin PD; Lasseter KC; Brown CD; Windass AS; Raza A
Clin Pharmacol Ther; 2004 May; 75(5):455-63. PubMed ID: 15116058
[TBL] [Abstract][Full Text] [Related]
18. Construction of HEK293 cells stably expressing wild-type organic anion transporting polypeptide 1B1 (OATP1B1*1a) and variant OATP1B1*1b and OATP1B1*15.
Chen M; Qu BX; Chen XL; Hu HH; Jiang HD; Yu LS; Zhou Q; Zeng S
Pharmazie; 2016 Jun; 71(6):337-9. PubMed ID: 27455553
[TBL] [Abstract][Full Text] [Related]
19. Solitary Inhibition of the Breast Cancer Resistance Protein Efflux Transporter Results in a Clinically Significant Drug-Drug Interaction with Rosuvastatin by Causing up to a 2-Fold Increase in Statin Exposure.
Elsby R; Martin P; Surry D; Sharma P; Fenner K
Drug Metab Dispos; 2016 Mar; 44(3):398-408. PubMed ID: 26700956
[TBL] [Abstract][Full Text] [Related]
20. Ethnic variability in the plasma exposures of OATP1B1 substrates such as HMG-CoA reductase inhibitors: a kinetic consideration of its mechanism.
Tomita Y; Maeda K; Sugiyama Y
Clin Pharmacol Ther; 2013 Jul; 94(1):37-51. PubMed ID: 23443754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
